Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 OutlineOutline History of development programHistory of development program –Dr. Carol Bosken Introduction.

Slides:



Advertisements
Similar presentations
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Advertisements

1 Voriconazole NDAs and Empiric Antifungal Therapy of Febrile Neutropenic Patients Study 603 John H. Powers, M.D. Medical Officer Division.
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Clinical Trial Efficacy Senior Biostatistician Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut James Street, PhD.
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Luveris ® New Drug Application ( ) Kate Meaker, M.S. Statistical Reviewer Division of Biometrics II Kate Meaker, M.S. Statistical Reviewer Division.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,
Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.
Pulmonary-Allergy Drugs Advisory Committee January 17, FLOVENT ® DISKUS ® NDA , S004 GlaxoSmithKline Pulmonary-Allergy Drugs Advisory Committee.
Challenges of Non-Inferiority Trial Designs R. Sridhara, Ph.D.
Influence of Comorbid Depression and Antidepressant Treatment on Mortality for Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease by SSDI-eligibility.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
1 Statistical Review Dr. Shan Sun-Mitchell. 2 ENT Primary endpoint: Time to treatment failure by day 50 Placebo BDP Patients randomized Number.
CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
1 Controlling False Positive Rate Due to Multiple Analyses Controlling False Positive Rate Due to Multiple Analyses Unstratified vs. Stratified Logrank.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.
A 1 Physician’s Perspective: The Impact. A 2 Clinician’s Perspective Bartolome R. Celli, MD Professor of Medicine Tufts University Boston, MA.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Statistical Review of P Acorn’s CorCap Cardiac Support Device
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
Anastrozole (‘Arimidex’): a new standard of care?
1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
4S: Scandinavian Simvastatin Survival Study
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Division of Oncology Drug Products 1 AREAS OF MAJOR STATISTICAL CONCERNS IN THE M01 STUDY Overall (ITT Population) Finding Liver Metastasis Subgroup Finding.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.
내과 R2 이지훈 N Engl J Med Sep 8.
Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
SNDA ETHYOL FOR RADIATION INDUCED XEROSTOMIA.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Filming: 15th of Febuary 2016, London, UK
Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs Insulin Glargine U100 in Older Patients (≥65 years) with Type 2 Diabetes.
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Mark Rothmann U.S. Food and Drug Administration September 14, 2018
American College of Cardiology Presented by Dr. Stephan Windecker
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Comparison of Baseline Characteristics by Primary End Point
Presentation transcript:

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 OutlineOutline History of development programHistory of development program –Dr. Carol Bosken Introduction to efficacy resultsIntroduction to efficacy results Dr. Carol BoskenDr. Carol Bosken Efficacy results Efficacy results Ms. Feng Zhou Ms. Feng Zhou Safety results and summary – Dr. Carol Bosken History of development programHistory of development program –Dr. Carol Bosken Introduction to efficacy resultsIntroduction to efficacy results Dr. Carol BoskenDr. Carol Bosken Efficacy results Efficacy results Ms. Feng Zhou Ms. Feng Zhou Safety results and summary – Dr. Carol Bosken

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Outline of Presentation Statistical methods Results –Mortality – SCO30003 Dropout issue SFC compared to components US vs. Non-US –Exacerbations SFCB3024 SCO30003 –Multiplicity issues US vs. Non-US Statistical methods Results –Mortality – SCO30003 Dropout issue SFC compared to components US vs. Non-US –Exacerbations SFCB3024 SCO30003 –Multiplicity issues US vs. Non-US

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Statistical Methods Agreed with sponsor’s statistical methods and results –Mortality (SCO30003) Log-Rank test, stratified by smoking status Other pre-specified supportive analyses –Exacerbations (SFCB3024, SCO30003) Negative Binomial model Poisson model Andersen Gill model Agreed with sponsor’s statistical methods and results –Mortality (SCO30003) Log-Rank test, stratified by smoking status Other pre-specified supportive analyses –Exacerbations (SFCB3024, SCO30003) Negative Binomial model Poisson model Andersen Gill model

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-Cause Mortality Results Study SCO30003 SFC vs. PLA: ∆ = 2.6% HR=0.82 (0.68, 1.00) p=0.052 Death rates at 3 yrs:

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Factors Affecting Interpretation of Results Study SCO30003 Dropout Low risk vs. High risk US vs. Non-US Dropout Low risk vs. High risk US vs. Non-US

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Percentage of Dropouts Overall and by Primary Reason Study SCO30003

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Dropout Issue Addressed dropout issue in 2 ways: –Dropouts for low and high risk subgroups Risk profile defined by baseline characteristics where low risk is defined by: –No history of myocardial infarction & –No COPD exacerbation during the year previous to baseline & –% predicted post-bron. FEV1 > 40% Mortality results by risk groups –On-treatment mortality Addressed dropout issue in 2 ways: –Dropouts for low and high risk subgroups Risk profile defined by baseline characteristics where low risk is defined by: –No history of myocardial infarction & –No COPD exacerbation during the year previous to baseline & –% predicted post-bron. FEV1 > 40% Mortality results by risk groups –On-treatment mortality

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Percentage of Dropouts by Subgroups

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-Cause Mortality Hazard Ratios (95% CI) for SFC vs. PLA by Selected Risk Groups

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-Cause Mortality by Risk Profile (SFC vs. PLA) Low Risk (26%) High Risk (74%) Death rates: 12.1% – PLA 7.9% - SFC ∆ = 4.2% HR = % CI (0.40, 0.99) Death rates: 16.1% – PLA 14.3% - SFC ∆ = 1.8% HR = % CI (0.71, 1.09)

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-Cause Mortality (SFC vs. PLA) On-Treatment Deaths Overall Deaths All-Cause Mortality (SFC vs. PLA) On-Treatment Deaths Overall Deaths Death rates: 15.2% - PLA 12.6%- SFC ∆ = 2.6% HR = %CI (0.7, 0.99) Death rates: 10.5% - PLA 8.1% - SFC ∆ = 2.4% HR = %CI (0.6, 1.01)

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Relationship of Risk Profile to Dropout & to Outcome Low risk patients remained on study longer than high risk patients regardless of randomized treatment Low risk patients show greater benefit from SFC over placebo compared to high risk patients –Supported by favorable on-treatment mortality results Dropouts in both treatment groups were at a higher risk of dying than patients remaining on treatment Low risk patients remained on study longer than high risk patients regardless of randomized treatment Low risk patients show greater benefit from SFC over placebo compared to high risk patients –Supported by favorable on-treatment mortality results Dropouts in both treatment groups were at a higher risk of dying than patients remaining on treatment

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-Cause Mortality SFC vs. PLA and Components SAL50 == SFC50/500 ?

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 COPD-related Mortality SFC vs. PLA and Components Death rate at 3 years: 6.3% - PLA, 6.4% - SAL, 7.3% - FP, 4.9% - SAL

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-cause Mortality By Region SFC vs. PLA

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-Cause Mortality (SFC vs. PLA) US Population (23%) Non-US Population (77%) Death rates: 13.9% - PLA 12.3% - SFC ∆ = 1.6% HR = % CI (0.58, 1.32) Death rates: 15.5% - PLA 12.7% - SFC ∆ = 2.8% HR = % CI (0.65, 1.00)

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 All-Cause Mortality US Population (23%) Non-US Population (77%) HR: SFC vs. SAL=0.83 (p=0.4) SFC vs. FP=0.91 (p=0.7) HR: SFC vs. SAL=0.96 (p=0.8) SFC vs. FP=0.74 (p=0.006)

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Summary of Mortality Result SFC showed a marginal survival benefit over placebo (∆=2.6%, p=0.052) and comparable results to SAL (∆=0.9%) SFC showed a smaller survival benefit in US (∆=1.6%) compared to other countries (∆=2.8%) SFC showed a greater survival benefit for low risk patients (∆=4.2%) compared to higher risk patients (∆=1.8%) SFC showed a marginal survival benefit over placebo (∆=2.6%, p=0.052) and comparable results to SAL (∆=0.9%) SFC showed a smaller survival benefit in US (∆=1.6%) compared to other countries (∆=2.8%) SFC showed a greater survival benefit for low risk patients (∆=4.2%) compared to higher risk patients (∆=1.8%)

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 COPD Exacerbation Endpoints

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 SCO30003 Study - Multiplicity (proposed in SAP in 1/06) All-cause mortality SFC vs. PLA Stop Exacerbation SFC vs. PLA Stop Exacerbation SFC vs. SAL p <= 0.05 p > 0.05 SGRQ SFC vs. PLA SFC vs. SAL Stop p > 0.05 p <= 0.05 p = 0.052

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Exacerbation Endpoint for SFCB3024 Moderately Severe and Severe

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Exacerbation Endpoint for SCO30003 Moderate and Severe

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 COPD Exacerbation Endpoints - Moderate/Severe Subjects had previous exacerbation history

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Exacerbation Endpoint for SCO30003 Moderate and Severe by Region (SFC vs. PLA)

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Moderate/Severe Exacerbation Study SCO30003 – US vs. Non-US

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Summary of COPD Exacerbation No statistical adjustments for multiple comparisons were made for this secondary endpoint. SFC showed a benefit in reduction for COPD moderate/severe exacerbation compared to placebo in both studies The comparison of SFC to SAL and FP showed a similar trend in both studies; however, comparisons are only significant in Study SCO30003 SFC showed a smaller benefit in US population compared to Non-US population in Study SCO30003 No statistical adjustments for multiple comparisons were made for this secondary endpoint. SFC showed a benefit in reduction for COPD moderate/severe exacerbation compared to placebo in both studies The comparison of SFC to SAL and FP showed a similar trend in both studies; however, comparisons are only significant in Study SCO30003 SFC showed a smaller benefit in US population compared to Non-US population in Study SCO30003

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 Thank You! ****